Acorda Therapeutics Management
Management criteria checks 2/4
Acorda Therapeutics' CEO is Ron Cohen, appointed in Jan 1995, has a tenure of 29.58 years. total yearly compensation is $996.33K, comprised of 62.7% salary and 37.3% bonuses, including company stock and options. directly owns 0.6% of the company’s shares, worth $225.39. The average tenure of the management team and the board of directors is 6.3 years and 21.1 years respectively.
Key information
Ron Cohen
Chief executive officer
US$996.3k
Total compensation
| CEO salary percentage | 62.7% |
| CEO tenure | 29.6yrs |
| CEO ownership | 0.6% |
| Management average tenure | 6.3yrs |
| Board average tenure | 21.1yrs |
Recent management updates
Recent updates
Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?
Feb 21
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement
Dec 18Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?
Jun 05Acorda wins $16.5M in Ampyra arbitration case with Alkermes
Oct 17Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote
Oct 10Acorda inks license deal with Asieris for pre-clinical drug
Aug 29Acorda Therapeutics announces resignation of COO
Aug 19Acorda Therapeutics: Managing The Transition
Oct 04Acorda Therapeutics Continues To Maneuver For A Turnaround
Jul 24CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action
Jun 17Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now
May 26Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts
Mar 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$263m |
| Dec 31 2023 | US$996k | US$625k | -US$253m |
| Sep 30 2023 | n/a | n/a | -US$16m |
| Jun 30 2023 | n/a | n/a | -US$21m |
| Mar 31 2023 | n/a | n/a | -US$58m |
| Dec 31 2022 | US$984k | US$625k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$106m |
| Jun 30 2022 | n/a | n/a | -US$119m |
| Mar 31 2022 | n/a | n/a | -US$95m |
| Dec 31 2021 | US$2m | US$743k | -US$104m |
| Sep 30 2021 | n/a | n/a | -US$166m |
| Jun 30 2021 | n/a | n/a | -US$132m |
| Mar 31 2021 | n/a | n/a | -US$127m |
| Dec 31 2020 | US$2m | US$796k | -US$100m |
| Sep 30 2020 | n/a | n/a | US$49m |
| Jun 30 2020 | n/a | n/a | -US$222m |
| Mar 31 2020 | n/a | n/a | -US$232m |
| Dec 31 2019 | US$2m | US$796k | -US$273m |
| Sep 30 2019 | n/a | n/a | -US$329m |
| Jun 30 2019 | n/a | n/a | -US$79m |
| Mar 31 2019 | n/a | n/a | -US$6m |
| Dec 31 2018 | US$2m | US$796k | US$34m |
| Sep 30 2018 | n/a | n/a | -US$147m |
| Jun 30 2018 | n/a | n/a | -US$158m |
| Mar 31 2018 | n/a | n/a | -US$213m |
| Dec 31 2017 | US$2m | US$792k | -US$223m |
Compensation vs Market: Ron's total compensation ($USD996.33K) is above average for companies of similar size in the US market ($USD689.66K).
Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.
CEO
Ron Cohen (68 yo)
29.6yrs
Tenure
US$996,328
Compensation
Dr. Ron Cohen, M.D., serves as an Independent Director of ZWI Therapeutics, Inc. since January 2024. He has been the Founder of Acorda Therapeutics, Inc. since 1995 and has been its Chief Executive Officer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 29.6yrs | US$996.33k | 0.60% $ 225.4 | |
| CFO & Treasurer | 2.8yrs | US$611.55k | 0% $ 0 | |
| General Counsel & Corporate Secretary | 2.8yrs | US$661.57k | 0% $ 0 | |
| Executive Vice President of Human Resources | 9.6yrs | no data | no data | |
| Chief Commercial Officer | 2.9yrs | US$592.23k | 0.041% $ 15.2 | |
| Senior VP of Operations & Strategic Planning | no data | no data | no data | |
| Senior VP of Drug Development & Regulatory Affairs | no data | no data | no data | |
| Special Scientific Advisor | no data | US$10.00k | no data |
6.3yrs
Average Tenure
64yo
Average Age
Experienced Management: ACOR.Q's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 29.6yrs | US$996.33k | 0.60% $ 225.4 | |
| Independent Director | 2.6yrs | US$94.71k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 26.6yrs | US$82.65k | 0.0019% $ 0.7 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Chairman | 15.7yrs | US$140.22k | 0% $ 0 |
21.1yrs
Average Tenure
70yo
Average Age
Experienced Board: ACOR.Q's board of directors are seasoned and experienced ( 21.1 years average tenure).